Hybridization LC–MS/MS: An alternative platform to enable specific and sensitive quantification of Antibody–ASO conjugates
Analytica Chimica Acta · 2026-09 · 1416 · 345757
DOI: 10.1016/j.aca.2026.345757 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytica Chimica Acta, 2026-09. Verfasst von Guilherme J Guimaraes und 3 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney St, Cambridge, MA, 02142, USA. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Antibodies, Monoclonal, Immunoconjugates. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Biogen Inc.
Abstract (Originalsprache)
Antibody-antisense oligonucleotide (Ab-ASO) conjugates are an innovative class of therapeutics that merge the gene-modulation capabilities of ASOs with the tissue-targeting properties of monoclonal antibodies. Sensitive, selective, and reliable methods to quantify Ab-ASO conjugates in biological samples are critical to understand their pharmacokinetics, pharmacodynamics, toxicity, and biodistribution properties. While ligand-binding assay (LBA) approach is common, it is often limited by the need for multiple custom reagents and narrower dynamic range. In this work, we present a robust hybridization LC-MS/MS strategy for the quantitation of Ab-ASO conjugates using sequence-specific hybridization extraction. Discovery proteomics was utilized to identify and select high-specificity surrogate peptides for the antibody moiety. The method leverages a biotinylated complementary DNA probe to selectively enrich the conjugate through Watson-Crick base pairing, followed by tryptic digestion and LC-MS/MS quantitation of surrogate peptides. The assay was successfully qualified in mouse serum over the range of 10.0 - 10,000 ng/mL and applied to a single-dose pharmacokinetic study, demonstrating high analytical agreement with a benchmark LBA strategy. The LC-MS/MS approach provides a superior dynamic range, simplifies reagent requirements and offers an LC-MS based quantitation platform that was previously unavailable for Ab-ASO conjugate quantitation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney St, Cambridge, MA, 02142, USA.
- Chemical Biology and Proteomics, Biogen, 225 Binney St, Cambridge, MA, 02142, USA.
- Drug Metabolism and Pharmacokinetics, Biogen, 225 Binney St, Cambridge, MA, 02142, USA. Electronic address: long.yuan@biogen.com.
Förderung
- Biogen Inc
Zitieren
APA
Guimaraes, G. J., Jiang, T., Bajrami, B., & Yuan, L. (2026). Hybridization LC–MS/MS: An alternative platform to enable specific and sensitive quantification of Antibody–ASO conjugates. Analytica Chimica Acta, 1416, 345757. https://doi.org/10.1016/j.aca.2026.345757
Vancouver
Guimaraes GJ, Jiang T, Bajrami B, Yuan L. Hybridization LC–MS/MS: An alternative platform to enable specific and sensitive quantification of Antibody–ASO conjugates. Analytica Chimica Acta. 2026;1416:345757. doi:10.1016/j.aca.2026.345757
BibTeX
@article{Guimaraes2026,
author = {Guimaraes, Guilherme J and Jiang, Ting and Bajrami, Bekim and Yuan, Long},
title = {Hybridization LC–MS/MS: An alternative platform to enable specific and sensitive quantification of Antibody–ASO conjugates},
journal = {Analytica Chimica Acta},
year = {2026},
volume = {1416},
pages = {345757},
doi = {10.1016/j.aca.2026.345757}
}
EUVIMED